Repare Therapeutics announced a strategic shift to prioritize the advancement of its Phase 1 clinical programs, RP-1664 and RP-3467, along with exploring partnerships for other assets like Lunre+Camo.
Repare Therapeutics Inc. (“Repare” or the “Company”) (Nasdaq: RPTX), a leading clinical-stage precision oncology company, today announced a re-alignment of resources and a re ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback